Utility of serum prostate specific antigen doubling time (PSADT) in patients with androgen independent prostate cancer

Srinivas, Sandy; Balu, V.; King, Christopher R.

doi:10.1200/jco.2005.23.16_suppl.4631

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PSA‐DT in particular is emerging as an increasingly important determinant of prostate cancer biology and expected clinical course. The utility of PSA‐DT has been studied not only in patients with BCR, but also those patients undergoing watchful waiting [11,12], salvage radiation therapy [13,14] and treatment for hormone‐refractory prostate cancer [15,16].…”

Section: The Natural History Of Rising Psa Levelsmentioning

confidence: 99%

Clinical trials in patients with biochemically relapsed prostate cancer

2006

View full text Add to dashboard Cite

In this section there is a wide diversity of mini‐reviews, covering several areas of interest for readers. Authors from the USA write about clinical trials in patients with biochemically relapsed prostate cancer, again bridging the divide between medical oncologists and urologists who specialise in urological oncological surgery. The second paper is a joint one from Germany and the USA, bringing the reader up to date with advances in the treatment of stress urinary incontinence. Finally there are two papers from Australia describing the use of positron emission tomography in renal cancer and in prostate cancer.

show abstract

Section: The Natural History Of Rising Psa Levelsmentioning

confidence: 99%

Clinical trials in patients with biochemically relapsed prostate cancer

2006

View full text Add to dashboard Cite

show abstract

Role of Chemotherapy in Nonmetastatic Hormone-Refractory Prostate Cancer

Bellmunt

2009

European Urology Supplements

View full text Add to dashboard Cite

A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis

Armstrong¹,

Garrett-Mayer

Yang

et al. 2007

Clinical Cancer Research

344

269

View full text Add to dashboard Cite

Purpose: To develop a prognostic model and nomogram using baseline clinical variables to predict death among men with metastatic hormone-refractory prostate cancer (HRPC). Experimental Design: TAX327 was a clinical trial that randomized 1,006 men with metastatic HRPC to receive every three week or weekly docetaxel or mitoxantrone, each with prednisone. We developed a multivariate Cox model and nomogram to predict survival at 1, 2, and 5 years. Results: Ten independent prognostic factors other than treatment group were identified in multivariate analysis: (a) presence of liver metastases [hazard ratio (HR), 1.66; P = 0.019], (b) number of metastatic sites (HR, 1.63 if z2 sites; P = 0.001), (c) clinically significant pain (HR, 1.48; P < 0.0001), (d) Karnofsky performance status (HR, 1.39 if V70; P = 0.016), (e) type of progression (HR, 1.37 for measurable disease progression and 1.29 for bone scan progression; P = 0.005 and 0.01, respectively), (f) pretreatment prostate-specific antigen (PSA) doubling time (HR, 1.19 if <55 days; P = 0.066), (g) PSA (HR, 1.17 per log rise; P < 0.0001), (h) tumor grade (HR, 1.18 for high grade; P = 0.069), (i) alkaline phosphatase (HR, 1.27 per log rise; P < 0.0001), and (j) hemoglobin (HR, 1.11 per unit decline; P = 0.004). Despite the recent demonstration of palliative and survival benefits with docetaxel-based regimens, men with metastatic hormone-refractory prostate cancer (HRPC) have a poor prognosis, with a median survival of 16 to 20 months (1, 2). The biology of prostate cancer is heterogeneous, with expected survival depending on performance status, presence of visceral metastases, baseline prostate-specific antigen (PSA), advanced primary Gleason sum, baseline hemoglobin, lactate dehydrogenase, albumin, and alkaline phosphatase (3, 4). Nomograms have been developed as stratification tools for phase III clinical trials evaluating cytotoxic chemotherapy based on data from multiple studies that assessed prognostic factors (3 -5).Baseline PSA kinetics [PSA doubling time (PSADT) or PSA velocity] have not been shown conclusively to be an independent prognostic factor in HRPC, with most analyses based on retrospective reviews of relatively small numbers of patients (6 -9). These analyses were limited by the number of controllable covariates, the duration of follow-up, potential confounders, and measurement bias. Furthermore, past prognostic analyses are limited by the inclusion of various types of noncytotoxic therapy and did not include patients treated with docetaxel-based therapy (3, 4).In 2004, docetaxel was approved for the treatment of men with metastatic HRPC based on large multicenter randomized clinical trials (1, 2). The TAX327 study randomized 1,006 patients to receive one of two schedules of docetaxel or mitoxantrone, each given with low-dose prednisone, and showed an extension of overall survival, improvement in quality of life, pain control, PSA decline, and objective tumor response (2). A second phase III study using estramustine phosphate in combination w...

show abstract

Utility of serum prostate specific antigen doubling time (PSADT) in patients with androgen independent prostate cancer

Cited by 3 publications

References 0 publications

Clinical trials in patients with biochemically relapsed prostate cancer

Clinical trials in patients with biochemically relapsed prostate cancer

Role of Chemotherapy in Nonmetastatic Hormone-Refractory Prostate Cancer

A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis

Contact Info

Product

Resources

About